88 results about "Diabetic mouse" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of 1, 3-propane diamine or pharmaceutically acceptable salts thereof in preparation of medicines for preventing or treating diabetes. Experimental results show that 1, 3-propane diamine can obviously improve random blood glucose and fasting blood glucose of mice with type 2 diabetes mellitus, and 1, 3-propane diamine can obviously improve insulin resistance of model mice. According to the application, 1, 3-propane diamine is used for improving the blood sugar of patients with type 2 diabetes for the first time, an ideal treatment effect is achieved, a new treatment choice is provided for improving the blood sugar level through clinical application of 1, 3-propane diamine, and the application has extremely high application value and social benefits.

The invention relates to the technical field of functional probiotic screening and application, and particularly provides a bifidobacterium animalis subsp. Lactis (Bifidobacterium animalis subsp. Lactis) capable of relieving liver injury and regulating glycolipid metabolism and application of the bifidobacterium animalis subsp. Lactis. The preservation number of the bifidobacterium animalis subsp. Lactis is CGMCC No.31656, and the bifidobacterium animalis subsp. Lactis can effectively reduce blood sugar and blood fat of diabetic mice and relieve insulin resistance and has the capacity of relieving diabetic cardiomyopathy. The strain has wide application prospects in preparation of drugs for treating diabetes mellitus, liver injury and glycolipid metabolism.

The invention discloses an application of isoquercitrin in preparation of a medicine for improving insulin resistance and diabetes-related liver diseases, and belongs to the technical field of medicines. According to the application, a high-glucose and high-fat diet and streptozotocin combined method is adopted to successfully construct a type 2 diabetes mouse model; experiments find that the isoquercitrin can effectively relieve the symptoms of weight loss and water intake increase of T2DM mice, significantly reduce the fasting blood-glucose level and improve abnormal glucose tolerance; the isoquercitrin can reduce the liver index of a T2DM mouse, relieve fatty degeneration of the liver and repair a liver cell structure; by activating a PI3K / AKT signal channel, the isoquercitrin up-regulates the expression levels of PI3K, p-AKT, p-GSK3 and GLUT4 and down-regulates the expressions of GSK3 and PEPCK at the same time, so that the insulin resistance of T2DM mice is effectively improved, the fatty degeneration of the liver is improved, and the isoquercitrin has a protection or repair effect on liver injury.

The invention relates to mulberry oligosaccharide, a preparation method thereof and application of the mulberry oligosaccharide in blood sugar regulation and control. The mulberry oligosaccharide is obtained by processing mulberries through a large number of researches and specific process steps of enzymolysis, selenic acid modification, plasma treatment and the like, so that the stability of the mulberry oligosaccharide can be obviously improved, the inhibition capability on alpha-glucosidase is obviously improved, the sugar tolerance condition of diabetic mice is improved, the blood sugar level is stabilized, and the application prospect is wide. Meanwhile, the insulin sensitivity of the body can be improved, the insulin resistance degree can be improved, the absorption and utilization of insulin to glucose can be improved, the SOD activity of the body can be improved, and the MDA content can be reduced, so that the development of diabetes can be effectively slowed down. In addition, natural mulberry is used as a main preparation raw material, no harmful chemical component is added, the cost is low, the safety is good, and great social significance is achieved.

Provided is a Bifidobacterium bifidum strain, Bifidobacterium bifidum ibiome001, which can significantly reduce body weight gain and white adipose tissue weight gain of high fat diet-induced obese and diabetic mice, and enhances expression of lipolytic genes ATGL and HSL. Moreover, Bifidobacterium bifidum ibiome001 can significantly lower fasting blood glucose levels, area under curves (AUCs) of the oral glucose tolerance (OGTT) curve, plasma glycated hemoglobin levels and insulin levels of diabetic mice. It is suggested that Bifidobacterium bifidum ibiome001 is a promising potential probiotic strain for the treatment of metabolic syndrome such as obesity, diabetes and the like, which is more effective than other Bifidobacterium strains / compositions.

The invention relates to the technical field of biological medicines, in particular to a Chinese wolfberry all-component mixture and application thereof in treatment of diabetes mellitus. The Chinese wolfberry all-component mixture is prepared through the following steps: S1, taking Chinese wolfberry fruits, performing continuous extraction for three times, combining extracting solutions obtained by the three times of extraction, performing filtration, and performing concentration so as to obtain a Chinese wolfberry fruit extract; s2, taking leaf buds, carpopodium and branches of the Chinese wolfberry, performing continuous extraction for three times, combining the three extraction solutions, filtering, and concentrating to obtain a leaf bud / carpopodium / branch extract of the Chinese wolfberry; and S3, mixing the Chinese wolfberry fruit extract obtained in the step S1 with the Chinese wolfberry leaf bud / fruit stem / branch extract obtained in the step S2, filtering, performing graded purification by adopting an ultrafiltration method, intercepting 20-100kDa components, and sterilizing to obtain a Chinese wolfberry all-component mixture. The Chinese wolfberry all-component mixture disclosed by the invention can be used for remarkably reducing a plurality of biochemical index levels such as fasting blood-glucose, glycosylated hemoglobin, triglyceride and extremely low density lipoprotein of a mouse with type 2 diabetes mellitus.

The invention discloses a preparation rich in polygonatum sibiricum polypeptide and application of the preparation in diabetes mellitus. The composition is prepared from rhizoma polygonati polypeptide, semeglutide, astaxanthin, an active agent and a ferroptosis mixture. Pharmacodynamic experiments show that in a diabetic mouse model, fasting blood glucose can be remarkably reduced, the serum insulin level can be increased, renal function indexes can be improved, and expression of NLRP3 inflammation pathway related proteins (NLRP3, Caspase-1 and IL-1beta) in pancreatic tissue can be remarkably inhibited. By integrating multiple mechanisms of blood glucose reduction, oxidation resistance, inflammation resistance, ferroptosis resistance and the like, multi-target collaborative intervention is realized, the pharmaceutical composition is remarkably superior to a single component in the aspects of blood glucose reduction, pancreas islet function protection and complication alleviation, and a new clinical strategy is provided for treatment of diabetes mellitus, especially type 1 diabetes mellitus.

The present disclosure relates to a use of Lacticaseibacillus rhamnosus FMBL L23004 CNN in the preparation of a medicament for preventing or treating diabetes mellitus. The Lacticaseibacillus rhamnosus FMBL L23004 CNN was deposited with the China Center for Type Culture Collection (CCTCC) on 26 Jun. 2023 under the accession number CCTCC NO: M 20231099. The Lacticaseibacillus rhamnosus FMBL L23004 CNN strain has the effect of inhibiting the activity of α-glucosidase, α-amylase, and dipeptidyl peptidase IV. Administration of the strain can significantly lower oral glucose tolerance and insulin tolerance in Type 2 Diabetes Mellitus (T2DM) mice, reduce abnormal postprandial blood glucose fluctuations, decrease fasting blood glucose levels, lower fasting insulin levels, reduce blood lipid levels, and alleviate insulin resistance. The strain significantly improves the composition of the gut microbiome, increases the abundance and diversity of beneficial gut bacteria, and reduces the relative abundance of pathogenic bacteria.

The invention relates to the field of biological medicine, and discloses application of an acellular fat extract in preparation of a medicine for accelerating chronic wound healing. Researches show that CEFFE can improve healing of chronic wounds of diabetic mice. This is achieved by the pro-angiogenesis and anti-inflammatory activity of CEFFE. The existence of various growth factors in the CE FFE can explain the influence of the growth factors on the functions of epidermal cells, endothelial cells, fibroblasts and macrophages. CEFFEE may be used as a therapeutic drug for treating chronic wounds of diabetic patients, and is expected to improve the overall prognosis of the diabetic patients and improve the life quality of the patients.

The invention belongs to the technical field of polypeptide preparation and biological medicine, and particularly relates to a preparation method of Jingzhaotoxin polypeptide IX (JZTX-IX) and application of Jingzhaotoxin polypeptide IX in treatment of diabetes mellitus. A chilobrachys jingzhao toxin polypeptide IX coding gene, a 6 * His tag nucleotide sequence, a thrombin restriction enzyme cutting site nucleotide sequence and an MBP hydrotropy tag nucleotide sequence are connected to a prokaryotic expression vector for prokaryotic expression, and the expressed polypeptide is purified to obtain the chilobrachys jingzhao toxin polypeptide IX protein. The target polypeptide with high purity, complete disulfide bond folding and uniform conformation is obtained, so that the high purity and biological activity of the target polypeptide are ensured. On the basis, the treatment activity of the JZTX-IX on diabetes mellitus especially type II diabetes mellitus is found and verified, and the JZTX-IX can remarkably reduce fasting blood glucose of mice with the type II diabetes mellitus, improve glucose tolerance and insulin sensitivity, relieve polydipsia and polyuria symptoms and promote insulin secretion and islet cell proliferation.

This invention discloses a method for constructing a type 2 diabetes mouse model combining artificial intelligence prediction and multi-target knockout. The method involves acquiring and standardizing multi-omics data and baseline phenotypic data of mice to form a standardized modeling dataset; constructing an interaction map covering pancreatic β-cell function based on this data; selecting target target combinations and target phenotypic prediction results; generating construction instructions and submitting them to a controlled facility for multi-gene knockout modification to obtain modified mice and modification receipts; obtaining measured phenotypic data of the modified mice based on the modification receipts; comparing this data with the target phenotypic prediction results to generate phenotypic deviation metrics and phenotypic determination results; and registering the target target combinations, prediction results, measured phenotypic data, and modification receipts when the phenotypic determination results are satisfactory to form a type 2 diabetes composite mouse model. This invention achieves closed-loop optimization of AI-driven multi-target genetic modification, improving the efficiency and accuracy of constructing animal models of complex metabolic diseases.

This invention belongs to the fields of biomedicine and molecular biology, specifically relating to the application of the FER1L6 gene in the prevention and treatment of diabetes. In this application, the expression of GLUT4 is increased by inhibiting the expression of FER1L6, thereby improving the related physiological metabolism in diabetic organisms. This physiological metabolism includes glucose uptake, lipid metabolism, and oxidative stress damage. Experimental results show that FER1L6 is highly expressed in type 2 diabetic mice and insulin-resistant HepG2 cells; reducing FER1L6 expression significantly increases GLUT4 expression, ultimately improving lipid metabolism and oxidative stress damage in diabetic mice, while also enhancing cellular glucose uptake. Therefore, it can be concluded that FER1L6 is a good regulatory target for the prevention and treatment of type 2 diabetes based on the GLUT4 pathway. Based on this target, new technical approaches can be provided for the prevention and control of type 2 diabetes.

The invention discloses a type 2 diabetes mellitus mouse model construction method combining artificial intelligence prediction and multi-target knockout. Acquiring and standardizing mouse multi-omics data and phenotype baseline data to form a standardized modeling data set; constructing an interaction map covering the functions of the pancreatic beta cells on the basis of the data; screening to obtain a target combination and a target phenotype prediction result, generating a construction instruction, and submitting the construction instruction to a controlled facility to execute multi-gene knockout transformation, so as to obtain a transformed mouse and a transformation receipt; acquiring actual measurement phenotype data of the transformed mouse based on the transformation receipt, and comparing the actual measurement phenotype data with a target phenotype prediction result to generate phenotype deviation measurement and a phenotype judgment result; and when the phenotype determination result is satisfied, registering the target combination, the prediction result, the actually measured phenotype data and the transformation receipt to form the type-2 diabetes mellitus composite mouse model. According to the method, AI-driven multi-target genetic modification closed-loop optimization is realized, and the efficiency and accuracy of complex metabolic disease animal model construction are improved.

The invention discloses a pharmaceutical composition for improving glucose and lipid metabolism disorder by combining N-p-coumaroyl octoamine and rotundine and application of the pharmaceutical composition, and belongs to the field of biological medicine and metabolic disease treatment. In a db / db diabetic mouse model, it is found that NTPC (10 mg / kg) or ROT (10 mg / kg) single drugs can improve hyperglycemia and insulin resistance and reduce blood fat, and low-dosage combination (5 mg / kg of NTPC and 5 mg / kg of ROT) shows the most significant metabolism improvement effect which is obviously better than that of a single drug group. In an in-vitro fatty acid stimulation model, lipid accumulation in cells can be more remarkably reduced through combination of the two drugs, and fatty acid synthesis genes are inhibited.

The invention provides application of nitraria tangutorum bobr extract in preparation of products for regulating glycolipid metabolism disorder, and relates to the technical field of plant extract application. The nitraria macrocarpa extract is a composition rich in alkaloid and flavonoid compounds, wherein the sum of the content of total alkaloid and the content of total flavonoids is not lower than 85% of the total weight of the extract. The extract is prepared through the processes of fresh fruit juicing, alcohol precipitation impurity removal and AB-8 macroporous resin gradient elution. Experiments show that the extract can significantly reduce fasting blood glucose of type 2 diabetes mice induced by high-fat and high-sugar diet combined with STZ, improve sugar tolerance and insulin resistance, and synchronously regulate the blood fat level, and shows an excellent glucose and lipid metabolism synergistic improvement effect. The extract disclosed by the invention provides a choice for developing a safe and effective glycolipid metabolism regulator.

This application belongs to the field of biomaterials, specifically relating to an antibacterial polymeric derivative of F127 with terminal modification of acetyl bromide, its preparation method, and its application. This application obtains F127AcBr by terminal modification of polymeric F127 with acetyl bromide via an acylation reaction. Its good antibacterial effect and biocompatibility were verified in vitro using plate antibacterial assays against Staphylococcus aureus and Escherichia coli, as well as live / dead staining assays of L929 cells and HUVEC cells. This application optimized the concentration of F127AcBr and loaded it into an MS hydrogel system. Excellent biocompatibility was confirmed in a diabetic mouse wound model using HE staining of mouse organs. Immunofluorescence staining against Staphylococcus aureus further confirmed the good antibacterial activity of F127AcBr.

The application belongs to the technical field of biological medicine, and discloses application of NP in preparation of a preparation for regulating metabolism of the intestines of senile type 2 diabetes. The NP is formed by hydrogen bond combination of a peptide from soft-shelled turtle eggs with naringenin in a mass ratio of 100:1, and the mass of the peptide is less than 3 kDa; the preparation is used for regulating phenotype-related metabolic modules and intestinal micro-ecological-related metabolic modules, remodeling the intestinal metabolic regulation network taking differential metabolites as a bridge, and thus systemically improving metabolic disorders related to senile type 2 diabetes. It is found that NP intervention can obviously correct abnormal total metabolic profiles of feces of senile type 2 diabetes mice, and make the disease type metabolic profile shift to a new steady state of intervention type. Non-targeted metabolomics analysis by LC-MS / MS shows that the overall metabolic profile of the high-dose NP group is closer to that of the classic hypoglycemic drug metformin group, indicating that NP has a significant metabolic remodeling capacity.

The invention belongs to the technical field of medicines, and particularly relates to application of urolithin A and beta-nicotinamide mononucleotide in preparation of a medicine for treating diabetes. The invention finds that when the urolithin A and the beta-nicotinamide mononucleotide are independently used, the hypoglycemic effect on diabetic mice cannot be realized, and when the urolithin A and the beta-nicotinamide mononucleotide are jointly used, the symptoms of diabetes and insulin resistance caused by high fat diet can be remarkably improved; the glucose tolerance and the insulin tolerance are improved; meanwhile, the content of low-density lipoprotein and cholesterol in a mouse body is reduced, so that the risk of thrombus occurrence is reduced; in addition, combined medication can significantly reduce liver cell lipid accumulation and improve mitochondrial morphological abnormality. The invention provides a brand new technical scheme and experimental basis for treating diabetes caused by high fat diet and relieving insulin resistance, and has important medical application value.

The invention belongs to the technical field of polypeptide preparation and biological medicine, and particularly relates to a preparation method of Jingzhaotoxin polypeptide XI (JZTX-XI) and application of Jingzhaotoxin polypeptide XI (JZTX-XI) in treatment of diabetes mellitus. A Jingzhaotoxin polypeptide XI coding gene, a nucleotide sequence of a 6 * His tag, a nucleotide sequence of a thrombin restriction enzyme cutting site and a nucleotide sequence of an MBP hydrotropy tag are connected to a prokaryotic expression vector for prokaryotic expression, and a target polypeptide which is high in purity, complete in disulfide bond folding and uniform in conformation is obtained through purification. The purity and the biological activity are relatively high. Meanwhile, the treatment activity of the JZTX-XI in the aspect of diabetes is verified, and it is found that the JZTX-XI can remarkably reduce fasting blood glucose of mice with type II diabetes, remarkably up-regulate a glucose transport regulation gene Glut2, improve glucose tolerance and insulin sensitivity, relieve polydipsia and polyuria symptoms and promote insulin secretion and islet cell proliferation.

This invention belongs to the field of biomedical technology and discloses the application of NP in the preparation of a glycemic regulator for aging type 2 diabetes. The NP is a nanoscale complex formed by hydrogen bonding of turtle egg peptide with a molecular weight less than 3 kDa and naringenin at a mass ratio of 100:1. The formulation promotes liver glycogen synthesis and repairs pancreatic tissue structure and pancreatic β-cell function by activating the hepatic IRS1 / PI3K / AKT / GSK-3β signaling pathway and upregulating GLUT2 protein expression. The NP provided by this invention can significantly reduce fasting blood glucose levels in aging type 2 diabetic mice, improve oral glucose tolerance, and reduce the area under the blood glucose curve. Simultaneously, by restoring insulin signal transduction, it significantly reduces the insulin resistance index and improves the insulin sensitivity index, with an improvement level approaching that of the classic hypoglycemic drug metformin.

The invention provides a preparation method and application of an anti-IL-11 antibody modified Treg cell, and belongs to the technical field of genetic engineering.The preparation method of the anti-IL-11 antibody modified Treg cell comprises the steps that after the Treg cell and umbilical cord blood pluripotent stem cells are co-cultured, the Treg cell is separated and recycled, an anti-IL-11 antibody is adopted for modification, and the anti-IL-11 antibody modified Treg cell is obtained; the nucleotide sequence of the anti-IL-11 antibody is as shown in SEQ ID NO. 2 in the sequence table. In the co-culture process, stem cells are used for providing an immune microenvironment, promoting Treg cell amplification and enhancing the inhibition ability of Treg cells, and obtaining the specific recognition ability of pancreas islet beta cell antigens, so that autoimmune attacks are inhibited more accurately; the nucleotide sequences of the heavy chain and the light chain of the anti-IL-11 antibody are optimized, and the anti-IL-11 antibody has higher efficacy in treatment of diabetic mice.

The invention discloses an application of miR-100 sponge in preparation of a medicine for treating type 2 diabetes mellitus. The miR-100 sponge can inhibit miR-100 in a targeted manner and close the expression of miR-100 in beta cells. The nucleic acid construct is further prepared from the nucleic acid construct, AAV8-mmu-miR-100 Sponge (AAV-Sponge) is injected into pancreatic ducts of obese diabetes mellitus mice, after treatment is conducted for 4 weeks, it is found that the sugar tolerance of the mice in a treatment group is improved, the GSIS function of beta cells is improved, and the nucleic acid construct is expected to be further applied to preparation of the medicine for treating the type 2 diabetes mellitus. The problems that current treatment methods for type 2 diabetes mellitus are deficient and the treatment cost is high are solved.

The invention relates to the technical field of microbial engineering, and particularly discloses application of bifidobacterium breve i1088 metagen in preparation of a blood sugar regulating product. The bifidobacterium breve i1088 metabolite can play a biological function through a key metabolite 5-HIAA, stimulate human colorectal adenocarcinoma cells to secrete GLP-1 and up-regulate GCG gene expression so as to regulate the blood sugar level, has multiple biological activities (such as oxidation resistance and glycosidase activity inhibition), and can be used for preparing a medicine for treating cancer. The method has obvious advantages and effects in the fields of food science, biotechnology, nutrition and health care and the like. Animal experiments prove that the bifidobacterium breve i1088 metagen has the effect of remarkably reducing the fasting blood-glucose of a diabetic mouse; the bifidobacterium breve i1088 metagen shows good alpha-glucosidase and alpha-amylase inhibitory activity in an in-vitro experiment, and can be used for development and application of hypoglycemic products.

The invention discloses an application of a jerusalem artichoke tuber alcohol extract in preparation of a medicine for treating type 2 diabetes mellitus, and belongs to the technical field of medicines, the chemical components of the jerusalem artichoke tuber alcohol extract are mainly flavonoid substances, and the jerusalem artichoke tuber alcohol extract can remarkably recover the weight of a mouse with the type 2 diabetes mellitus and improve glucose metabolism indexes such as fasting blood-glucose and oral glucose tolerance; meanwhile, insulin sensitivity is stimulated to secrete insulin, and the functions of pancreatic beta cells are recovered; in addition, the concentration of biochemical indexes such as total cholesterol and triglyceride in the liver is reduced, lipid metabolism of the liver is improved, and a new direction is provided for research and development of natural plant source hypoglycemic products.

The invention discloses a medicine for treating diabetic retinopathy and application of scorpion venom heat-resistant synthetic peptide in treating the disease, belongs to the field of research and development of polypeptide medicines, and is used for treating or preventing the diabetic retinopathy (DR). Experimental results show that the scorpion venom heat-resistant synthetic peptide (SVHRSP) has the effect of preventing and treating diabetic retinopathy (DR) on a streptozotocin (STZ)-induced mouse experimental diabetes model, and can repress retinal function impairment caused by impairment of streptozotocin (STZ)-induced diabetic mouse retinal photoreceptor cells and retinal nerve inner layer cells; and retina structure damage caused by thinning of the retina thickness of a diabetic mouse induced by STZ (streptozotocin) is inhibited.

This invention provides a hypoglycemic subspecies of Bifidobacterium animalis (Liver) and its applications. The Bifidobacterium animalis (Liver) subspecies is named Tianshan-1 and is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 35821 on September 5, 2025. Cell experiments show that Tianshan-1 significantly promotes the secretion of GLP-1 from human colorectal adenocarcinoma cells NCI-H716 and upregulates GCG gene expression levels. Animal experiments confirm that this strain significantly increases serum GLP-1 concentration in diabetic mice and reduces fasting blood glucose and glycated hemoglobin levels, with no significant difference in hypoglycemic effect compared to the positive control. This strain is a food-grade safe probiotic with a clear mechanism of action and stable effects, providing a safe, long-lasting, and industrially viable new probiotic resource for diabetes prevention and treatment, with broad application prospects.

The application provides a preparation of gramicidin and an antibacterial hydrogel preparation of the gramicidin, and discloses medical uses of the gramicidin, and provides a recombinant gramicidin, heterologous expression of the gramicidin is realized by constructing a Pichia pastoris recombinant strain, and the antibacterial activity of the gramicidin is retained, and the method has the advantages of simplicity and rapidness. Meanwhile, the hydrogel preparation of the gramicidin provided by the application shows good potential for treating wound infection of a diabetic mouse, and has the performance of rapid adhesion and hemostasis, lays a foundation for development of a new antibacterial drug, and provides a new direction for treatment of chronic inflammatory wounds and open bleeding.

This invention provides *Pediococcus lactis* SHI03 and its application in alleviating insulin resistance and type 2 diabetes, belonging to the field of microbial technology. This invention provides *Pediococcus lactis* SHI03, with accession number CCTCC No: M 20242686, and confirms that this strain possesses in vitro α-glucosidase inhibitory activity, exhibiting excellent probiotic and hypoglycemic effects. This invention further provides microbial products containing *Pediococcus lactis* SHI03, including *Pediococcus lactis* SHI03 fermentation broth, *Pediococcus lactis* SHI03 fermentation supernatant, and *Pediococcus lactis* SHI03 cells, and their applications in alleviating high-fat diet-induced insulin resistance and reducing fasting blood glucose in type 2 diabetic mice.

The invention relates to the technical field of improvement of diabetic cardiomyopathy, and particularly discloses an application of a Spexin active polypeptide in preparation of a medicine for improving diabetic cardiomyopathy, the amino acid of the Spexin active polypeptide is NWTPQAMLYLKGAQ, and the medicine for improving diabetic cardiomyopathy is used for improving cardiomyopathy of mammals. The medicine for improving the diabetic cardiomyopathy further comprises pharmaceutically acceptable auxiliary materials and / or carriers, the Spexin active polypeptide is applied to preparation of the medicine for improving the diabetic cardiomyopathy, a new treatment thought and means are provided for the refractory disease, and animal experiments prove that the medicine has a good treatment effect on the diabetic cardiomyopathy. The Spexin active polypeptide can effectively reduce the blood sugar, the body weight and the length ratio of the heart to the tibia of a diabetic mouse, remarkably improve the cardiac function of the diabetic mouse and reduce the E / A peak, so that cardiac hypertrophy and cardiac dysfunction caused by diabetes are effectively relieved, and a remarkable treatment effect is shown.

The invention discloses a curcumin nanocrystal aloe gel powder composition and application thereof, and belongs to the technical field of food, health care products and medicines. The curcumin nanocrystal aloe gel powder composition is characterized in that no surfactant is added; the curcumin nanocrystal is prepared only by using the aloe gel powder as a stabilizer to improve the dissolution rate of the curcumin, and the mass ratio of the curcumin to the aloe gel powder is (1: 1)-(1: 200). The preparation method comprises the following steps: preparing a curcumin nanocrystal aloe gel suspension by adopting a wet grinding or high-pressure homogenization method, and then drying by adopting a freeze-drying or spray-drying process. The curcumin nanocrystalline aloe gel powder disclosed by the invention has the effects of reducing blood sugar and blood fat, improving drinking water, ingestion and body weight, regulating intestinal flora and increasing abundance of hypoglycemic bacteria on diabetic mice, so that main visceral organs are protected, and the effects of improving diabetes and complications thereof are achieved.